ATE33558T1 - Stabilisierung von influenzavirusimpfstoffen. - Google Patents

Stabilisierung von influenzavirusimpfstoffen.

Info

Publication number
ATE33558T1
ATE33558T1 AT82111958T AT82111958T ATE33558T1 AT E33558 T1 ATE33558 T1 AT E33558T1 AT 82111958 T AT82111958 T AT 82111958T AT 82111958 T AT82111958 T AT 82111958T AT E33558 T1 ATE33558 T1 AT E33558T1
Authority
AT
Austria
Prior art keywords
stabilization
virus vaccines
influence virus
vaccines
influence
Prior art date
Application number
AT82111958T
Other languages
English (en)
Inventor
Costantino Peter Cerini
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of ATE33558T1 publication Critical patent/ATE33558T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT82111958T 1982-04-06 1982-12-23 Stabilisierung von influenzavirusimpfstoffen. ATE33558T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/366,296 US4537769A (en) 1982-04-06 1982-04-06 Stabilization of influenza virus vaccine
EP82111958A EP0090886B1 (de) 1982-04-06 1982-12-23 Stabilisierung von Influenzavirusimpfstoffen

Publications (1)

Publication Number Publication Date
ATE33558T1 true ATE33558T1 (de) 1988-05-15

Family

ID=23442454

Family Applications (1)

Application Number Title Priority Date Filing Date
AT82111958T ATE33558T1 (de) 1982-04-06 1982-12-23 Stabilisierung von influenzavirusimpfstoffen.

Country Status (6)

Country Link
US (1) US4537769A (de)
EP (1) EP0090886B1 (de)
JP (1) JPS58183628A (de)
AT (1) ATE33558T1 (de)
CA (1) CA1213215A (de)
DE (1) DE3278344D1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631191A (en) * 1985-06-20 1986-12-23 Biotechnology Research Partners, Ltd. Methods and compositions useful in preventing equine influenza
WO1991009940A1 (en) * 1989-12-29 1991-07-11 Symex Corp. Stable formulation of viral neuraminidase
US5629020A (en) 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
CA2125400A1 (en) * 1991-12-18 1993-06-24 Gordon L. Amidon Soybean protein or hydrolyzates in pharmaceutical compositions to protect bioactive peptides from enzymatic inactivation
US6337070B1 (en) 1993-04-29 2002-01-08 Takara Shuzo Co., Ltd. Polypeptides for use in generating anti-human influenza virus antibodies
US6153592A (en) * 1992-11-09 2000-11-28 Port Systems, Llc Enhancing the bioavailability of proteolytically labile therapeutic agents
US5709861A (en) * 1993-04-22 1998-01-20 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US5958457A (en) * 1993-04-22 1999-09-28 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US5453533A (en) * 1994-04-14 1995-09-26 The University Of Alabama At Birmingham Inhibitors of influenza virus neuraminidase and methods of making and using the same
US5985859A (en) * 1994-04-14 1999-11-16 The University Of Alabama Methods of inhibiting bacterial sialidase
DE69533188T2 (de) * 1994-10-11 2005-02-17 Ajinomoto Co., Inc. Stabilisierte transglutaminase und diese enthaltende enzymatische zubereitung
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
US20060141483A1 (en) * 2004-12-23 2006-06-29 Calton Gary J Stabilization of viral compositions
US20060190188A1 (en) * 2005-01-25 2006-08-24 Nauta Jozef J Methods and systems for determining lot consistency
CA2552596A1 (en) * 2005-08-09 2007-02-09 Solvay Pharmaceuticals B.V. Methods and systems for determining mid-value titers
GB0614460D0 (en) * 2006-07-20 2006-08-30 Novartis Ag Vaccines
MY149924A (en) * 2007-03-09 2013-10-31 Otsuka Pharma Co Ltd Lyophilized preparation comprising influenza vaccine, and method for preparation thereof
KR20090096890A (ko) * 2008-03-10 2009-09-15 전남대학교산학협력단 대장균에서 조류인플루엔자 바이러스의 뉴라미니다제 ｎ1을발현하기 위한 벡터 및 방법, 이의 사용방법, 및뉴라미니다제 저해제
US9119866B2 (en) * 2008-04-08 2015-09-01 Huiru Wang Glycan-based drugs, therapies and biomarkers
CN102482666B (zh) 2009-07-06 2017-02-08 变异生物技术公司 制备囊泡的方法和由其产生的制剂
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
IN2012DN06277A (de) * 2009-12-28 2015-09-25 Dsm Ip Assets Bv
CN102178686B (zh) * 2010-01-07 2016-01-13 王慧茹 多糖相关疾病的药物和疫苗及免疫测定产品
ES2568942T3 (es) * 2010-04-27 2016-05-05 Universidad Manuela Beltrán Vacuna biológica autóloga contra el cáncer
CN103096922B (zh) * 2010-07-06 2019-08-06 变异生物技术公司 用于治疗流行性感冒的组合物和方法
KR101949270B1 (ko) * 2010-11-30 2019-02-19 (주)아모레퍼시픽 펩타이드 또는 단백질 안정화제
BR112013017939B1 (pt) 2011-01-13 2022-11-16 Variation Biotechnologies Inc Composição imunogênica liofilizada termoestável, uso e método para preparação da mesma
US11060068B2 (en) * 2011-06-28 2021-07-13 Leukocare Ag Stabilisation method for viruses or bacteria
EP2802353A4 (de) 2012-01-12 2015-12-02 Variation Biotechnologies Inc Zusammensetzungen und verfahren zur behandlung von virusinfektionen
CN104244984B (zh) 2012-01-27 2020-03-31 变异生物技术公司 用于治疗剂的方法和组合物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3143470A (en) * 1961-04-24 1964-08-04 Parke Davis & Co Rabies virus propagation in embryonic cells maintained in a medium containing pancreatic digest of casein
US3156620A (en) * 1962-01-10 1964-11-10 American Cyanamid Co Attenuated live rabies vaccine and method of preparing the same
DE1183629B (de) * 1962-12-21 1964-12-17 Behringwerke Ag Verfahren zur Stabilisierung biologisch aktiven Materials
US3422188A (en) * 1965-08-17 1969-01-14 American Cyanamid Co Tissue culture hog cholera vaccine
US3629399A (en) * 1967-09-05 1971-12-21 Behringwerke Ag Stable poliomyelitis vaccines
US3585266A (en) * 1969-02-24 1971-06-15 Dow Chemical Co Live rabies virus vaccine and method for the production thereof
US3674862A (en) * 1970-04-02 1972-07-04 Lilly Co Eli Live attenuated rabies virus vaccine and process therefor
US3783098A (en) * 1971-08-10 1974-01-01 Cornell Res Foundation Inc Highly potent,viable and stable cellfree virus preparations from cells infected with cell-associated viruses and method for obtaining the same
US4009258A (en) * 1972-09-25 1977-02-22 The Mount Sinai School Of Medicine Of The City University Of New York Influenza vaccine containing a recombinant, antigenically hybridized virus and method of using the same
US4132775A (en) * 1973-12-03 1979-01-02 Richardson-Merrell Inc. Infectious bovine rhinotracheitis virus vaccine and method of preparing and using the same
FR2262962B1 (de) * 1974-03-05 1977-11-04 Science Union & Cie
US4195076A (en) * 1974-03-05 1980-03-25 Science Union Et Cie, Societe Francaise De Recherche Medicale Process for the preparation of hemagglutinin from viral sources and methods of utilizing same
US4287178A (en) * 1974-03-25 1981-09-01 Pitman-Moore, Inc. Feline rhinotracheitis vaccine and production and use thereof
US4029763A (en) * 1974-08-05 1977-06-14 Mount Sinai School Of Medicine Of The City University Of New York Influenza vaccine containing purified neuraminidase antigen and method of using the same
US4058598A (en) * 1974-10-18 1977-11-15 Harold Stern Cytomegalovirus attenuation method and vaccine
US3944469A (en) * 1974-11-21 1976-03-16 Pitman-Moore, Inc. Feline calicivirus vaccine and production thereof
US3937812A (en) * 1974-11-21 1976-02-10 Pitman-Moore, Inc. Feline calicivirus vaccine and production thereof
US3961046A (en) * 1974-12-02 1976-06-01 American Cyanamid Company Mumps vaccine and preparation thereof
US4040904A (en) * 1975-07-21 1977-08-09 Slater Eban A Novel rabies virus vaccine and processes
US4147772A (en) * 1976-02-03 1979-04-03 Merck & Co., Inc. Vaccine stabilizer
US4278662A (en) * 1979-10-16 1981-07-14 Smith Kline - Rit Attenuated influenza type A virus vaccine
US4273762A (en) * 1979-12-03 1981-06-16 Merck & Co., Inc. Lyophilization process for live viral compositions
US4338335A (en) * 1980-02-05 1982-07-06 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation

Also Published As

Publication number Publication date
EP0090886A3 (en) 1984-09-26
DE3278344D1 (en) 1988-05-26
EP0090886A2 (de) 1983-10-12
JPS58183628A (ja) 1983-10-26
CA1213215A (en) 1986-10-28
EP0090886B1 (de) 1988-04-20
US4537769A (en) 1985-08-27

Similar Documents

Publication Publication Date Title
DE3278344D1 (en) Stabilization of influenza virus vaccine
DE69332831T2 (de) Rekombinanter schweinepocken-virus
ATE141946T1 (de) Hiv-2-virusvarianten
ATE236981T1 (de) Von menschlichen t-zellen immunodominante epiropen des virus der c-hepatitis
DK0538437T3 (da) Immunstimulerende og immunforstærkende, rekonstituerede influenzavirosomer og vacciner indeholdende dem
DE69823046D1 (de) Praktische in vitro sialylierung von rekombinanten glykpproteinen
IT8247706A0 (it) Procedimento per la produzione di virus vaccini
FR2632863B2 (fr) Virus du fowlpox recombinant et vaccins derives de ces virus
DK0405867T3 (da) Hidtil ukendte forbindelser
DE69129115D1 (de) Neues verfahren zur behandlung von depression
EP0108115A4 (de) Hitzestabilisierung von plasmaproteinen.
DK606285D0 (da) Vaccine mod rabies samt fremgangsmaade til fremstilling deraf
BG96323A (bg) Нов полипептид и анти-нiv лекарство,получено от него
ES8403319A1 (es) Nuevas vacunas contra la bronquitis infecciosa.
DE69013471D1 (de) Methode zur Stabilisierung von rekombinanten Hepatitis-B-Virus-Oberflächenproteinen aus Hefe.
DK201879A (da) Fremgangsmaade til stabilisering af prostacyclinforbindelser
FI890116A0 (fi) Icke-reverterande rna-virus.
ES8800358A1 (es) Un procedimiento para preparar un polipeptido hibrido.
AP9100296A0 (en) Peptides and analogues and mixtures thereof for detecting antibodies to HTLV-1 and HTLV11 viruses.
DE68920502D1 (de) Pseudorabiesvirus-Impfstoff.
DE68920345D1 (de) Lebendes Kombinationsvakzin.
ATE255594T1 (de) Hepatitis b inhibitoren
ES2054841T3 (es) Vector viral y adn recombinante que codifica para una o unas proteinas de estructura (ha, f y/o np), de un morbilivirus.
ATE20230T1 (de) Spasmolytisch wirksames (+)s-enantiomer von secoverin.
NO902491D0 (no) Proteiner, vaksiner og nukleinsyrer.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee